Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Wellicht makkelijk alle ontwikkelingen betreffende HIV/AIDS, in 1 draadje te persen. Dirk
DJ Annan: 9 Cos To Help Provide Acess To HIV/AIDS Treatment 07/25/2006 Dow Jones News Services (Copyright © 2006 Dow Jones & Company, Inc.) UNITED NATIONS (AP)--Nine pharmaceutical and diagnostic companies have pledged to try to help meet the goal of providing universal access to HIV/AIDS prevention and treatment by 2010, Secretary-General Kofi Annan said Monday. Annan issued a statement after a private meeting between senior U.N. officials and top executives of the nine leading companies from the United States, Britain, India and South Africa to discuss ways to step up the response to the AIDS epidemic. "I am pleased that the companies I met with today pledged to continue their efforts, in line with international commitments toward the goal of being as close as possible to universal access by 2010," he said. Annan said the companies have made a commitment to the following measures: - To make their products more affordable, accessible and appropriate for use in low- and middle-income countries; - To register their HIV medications and diagnostic tools as widely as possible, including in developing countries; - To give greater priority to research and development of HIV medicines and diagnostic tools for children; - To increase investment in research and development of new HIV-related medications and diagnostic tools including vaccines and female-controlled technologies such as microbicides; - To continue to make arrangements with third-party manufacturers for licenses and the transfer of technology to make HIV medications and diagnostic tools more affordable and accessible. The United Nations agreed to devise, promote and update guidelines on HIV/AIDS diagnosis, treatment and product quality for adults and children. It will also step up its work with all partners to ensure sustained political leadership, adequate resources and better access to voluntary testing and counseling, Annan said. He said all participants stressed the importance of intellectual property to encourage research and development, and they agreed that strengthening health care systems is essential to expand access to treatment and advanced prevent efforts. "Progress on all these fronts is essential if we are to win the fight against HIV/AIDS - the greatest challenge of our generation," Annan said. Participants at the meeting were Aspen Pharmacare of South Africa, Britain's GlaxoSmithKline and three Indian companies - Aurobindo Pharma Ltd., Hetero Drugs Ltd., and Raxbaxy Laboratories Ltd. Four U.S. companies also took part, Becton Dickinson, Bristol-Myers Squibb, Johnson & Johnson, and Merck & Co. Dirk
Met Gates' geld zoeken naar vaccin LEON WILLEMS Miljardairsechtpaar Gates schenkt $ 287 mln voor onderzoek naar een HIV-vaccin. Onderzoekers uit negentien landen moeten speuren naar innovatieve benaderingen voor vaccinonderzoek. Welke benaderingen zijn dat en welke zijn volgens deskundigen veelbelovend? Haast maken, dat willen Bill en Melinda Gates van de gelijknamige stichting. Ondanks vijfentwintig jaar onderzoek is er nog steeds geen vaccin dat aidsbesmetting kan voorkomen. Het is niet zo vreemd dat Gates een impuls wil geven. Deskundigen verwachten dat het nog wel tien jaar kan duren voordat er een aidsvaccin beschikbaar is. Tien jaar is zeer lang als je een epidemie wilt bestrijden. Indien er geen vaccin gevonden wordt, zullen in het jaar 2020 alleen al in zuidelijk Afrika ruim 2,5 miljoen aidsdoden te betreuren zijn, zo becijferde de wereldgezondheidsorganisatie WHO onlangs. Tegen die tijd heeft de epidemie inmiddels ook grote delen van Zuidoost-Azië en Oost-Europa in haar dodelijke greep. Wereldwijd lijden nu circa 40 miljoen mensen aan de ongeneeslijke ziekte. Vorig jaar stierven 3 miljoen mensen aan aids volgens cijfers van de WHO. Aids wordt veroorzaakt door het Humaan Immunodeficiëntie Virus (HIV). Het virus breekt het afweersysteem af. Daardoor wordt het lichaam vatbaar voor allerlei infecties en bepaalde vormen van kanker. Infectieremmers die het ziekteproces vertragen en de levensverwachting laten toenemen, zijn nuttig maar ze pakken de oorzaak van het probleem niet aan. De jongste donatie van Gates is erop gericht om meer coördinatie te brengen in de wereldwijde onderzoeksinspanningen. Tot nu toe is onderzoek te kleinschalig en versnipperd. Daarom verdeelt de Gates-stichting het geld over zestien consortia van onderzoeksinstituten en testlaboratoria. Die moeten verkennen wat de meest innovatieve benaderingen zijn voor onderzoek naar een aidsvaccin. Nieuwe vaccinkandidaten worden getest en testresultaten worden gedeeld met andere deelnemende onderzoeksconsortia. Zo kunnen de veelbelovende kandidaten met voorrang verder worden ontwikkeld. Vijf van de onderzoeksconsortia gaan op zoek naar een vaccin dat doeltreffende antilichamen kan opwekken (zie inzet). Tot nu toe is slechts een handvol zogeheten neutraliserende antilichamen voor HIV ontdekt. Dat moeten er flink meer worden. De moeilijkheid dergelijke antistoffen op te wekken wordt door wetenschappers gezien als een van de grootste obstakels voor het maken van een aidsvaccin. Een groep van zes instituten gaat onderzoek doen hoe menselijke cellen immuun kunnen worden gemaakt tegen besmetting met HIV. Bestaande vaccinkandidaten vertonen nog te grote tekortkomingen, zo oordeelt het deskundigenteam dat Gates bijstaat in de aanpakkeuze van een donateursproject. Maar wat maakt een aidsvaccin vinden zo moeilijk? 'Een fundamenteel probleem is het ontwikkelen van een preventief vaccin', legt Joep Lange uit. Hij is hoogleraar inwendige geneeskunde en directeur van het Center for Poverty-related Communicable Diseases dat is verbonden aan het Amsterdam Medisch Centrum. 'Daarvoor heb je neutraliserende antistoffen nodig', zegt Lange. 'Wetenschappers zijn jarenlang misleid in hun zoektocht omdat antistoffen die in het laboratorium wel een neutraliserende werking toonden dat niet deden in het menselijke lichaam. De antistoffen konden niet goed bij de plek waar ze moesten zijn.' Bovendien kent het virus veel verschillende gedaanten. 'Haast geen HIV-stam lijkt op de ander', zegt Lange. De aanpak van gestructureerd samenwerkende onderzoeksconsortia, zoals Gates beoogt, is niet nieuw. 'Wel de grootschaligheid is vernieuwend', weet Lange. Hij herinnert zich hoe enkele jaren geleden het International Aids Vaccin Initiative de knuppel in het hoenderhok gooide. 'Zij wilden een systematische aanpak in plaats van academisch geneuzel. Zij kregen ook financiering. Grote onderzoeksinstituten werden daar knap nerveus van.' Wat zijn volgens onderzoeker Lange de meest belovende onderzoeksporen? 'Wisten we dat maar', antwoordt hij. Het International Aids Vaccin Initiative bracht deskundigheid over neutraliserende antistoffen bij elkaar. Daar moet de oplossing vandaan komen. De vaccins die we nu hebben wekken cellulaire weerstand op maar niet de bescherming die neutraliserende antistoffen bieden.' De hamvraag is natuurlijk welke antistoffen het HIV-virus neutraliseren. Lange denkt dat onderzoek zich op de korte termijn moet richten op vaccinaire combinaties die cellulaire weerstand opwekken, bijvoorbeeld een combinatie van een DNA-vaccin en een pokvirus. 'Zo'n vaccin zal waarschijnlijk niet veel bescherming geven tegen besmetting maar zou het virus er voor langere tijd onder kunnen houden. Het ontwikkelen van een vaccin dat neutraliserende antistoffen opwekt en echt bescherming tegen infectie geeft, is langetermijnwerk.'technologie@fd.nl
=DJ Study Finds 4-Drug Treatment No Better Than 3 For HIV 08/14/2006 Dow Jones News Services (Copyright © 2006 Dow Jones & Company, Inc.) By Peter Loftus Of DOW JONES NEWSWIRES (This article was originally published Sunday) The addition of a GlaxoSmithKline PLC (GSK) HIV drug to a three-drug regimen for initial treatment of HIV infection provided no additional benefit compared with the three-drug treatment, a study concluded. The study, whose results were to be presented Sunday at the International AIDS Conference in Toronto, involved 765 HIV-infected patients who hadn't been treated before and was conducted between March 2001 and March 2005. About half were given three drugs: zidovudine, lamivudine and efavirenz. Glaxo sells the first two under the brands Retrovir and Epivir, respectively, while Bristol-Myers Squibb Co. (BMY) sells the third under the brand Sustiva. The other half of the patients were given the three drugs plus abacavir, which Glaxo sells under the brand Ziagen. The study found there was no significance difference in effectiveness between the two regimens. "High rates of virologic suppression achieved in this study support current guidelines that recommend" the three-drug regimen for initial treatment of HIV infection, the authors wrote in a study to be published in the Aug. 16 issue of the Journal of the American Medical Association. Adding the fourth drug, abacavir, "provided no additional benefit," wrote the authors, who included researchers at the Weill Medical College of Cornell University in New York. Some of the researchers have received grants and compensation from the drug companies. The study was funded by the National Institutes of Health, with medications supplied by the manufacturers. Another study presented at the AIDS conference suggested that using a single drug with a booster, instead of a standard three-drug regimen, may be an effective maintenance therapy for some HIV patients. This small pilot study involved 34 HIV-infected patients whose viral levels had already been reduced by using a regimen of at least three drugs. They were then switched to atazanavir, which is sold by Bristol under the brand Reyataz, and given a booster known as ritonavir, sold as Norvir by Abbott Laboratories (ABT). After 24 weeks, 91% of the patients had continued suppressed viral levels, according to the study, which also is being published in JAMA. The study's authors said the preliminary data suggest that a "simplified maintenance therapy" might be able to maintain virologic suppression in carefully selected HIV patients. But the authors wrote that a larger, randomized study is needed to confirm this. The authors have received grants and compensation from Bristol-Myers and Abbott; the study was funded by NIH, with drugs supplied by the manufacturers. - Peter Loftus; Dow Jones Newswires; 215-656-8289; peter.loftus@dowjones.com Dirk
Experimental HIV drug 'helps control virus' 12.59am Monday August 14, 2006 TORONTO - An experimental HIV drug in a new class called integrase inhibitors helps control the virus well combined with other drugs commonly used in AIDS cocktails, its maker Merck and Co. has reported. The findings, to be presented at an international AIDS meeting, offer a potential new weapon in the growing armoury of drugs that fight HIV. The drug mixtures can keep HIV patients healthy for years, although they are not a cure. Merck said the drug, known by its experimental name MK-0518, worked as well as older drugs to suppress the AIDS virus when combined with Gilead Sciences' tenofovir, known commercially as Viread and GlaxoSmithkline's lamivudine, sold under the brand name Epivir. They compared the new drug with a similar cocktail using Bristol Myer Squibb's efavirenz, sold under the brand names Sustiva and Stocrin. For the study, 198 HIV-infected patients took one or the other mixture for 24 weeks. Both combinations lower viral load - the amount of the virus be found in blood. Suppressing the virus limits the damage it can do to a patient's immune system. "This early study showed a rapid and significant reduction in viral load up to 24 weeks with MK-0518," Dr. Martin Markowitz of the Aaron Diamond AIDS Research Centre in New York, who led the study, said in a statement. "This study should lend further insight into the potential of HIV integrase inhibitors as a new and exciting class of antiretroviral agents." There are several classes of HIV drugs, also known as antiretroviral drugs. Each class attacks the virus at a different point in its cycle of replication. Combining the drugs in a cocktail suppresses the virus even more, but eventually the virus in a patient's body escapes the effects of drugs so new approaches and combinations are needed to control it. When the human immunodeficiency virus infects a cell, usually an immune system cell called a T-cell, it attaches to the cell, pierces it and inserts its own genetic material. The viral DNA reprogrammes the cell, in essence hijacking it, and forces it to produce copy after copy of the virus, which it pumps into the blood to infect other cells. The integrase inhibitors stop the insertion of the HIV viral DNA into human DNA, shutting down the virus factory. Other HIV drugs target other enzymes involved in this hijacking process. Several companies are working on integrase inhibitors but none has been approved yet. - REUTERS
Future seen promising for AIDS vaccine By Maggie Fox, Health and Science Correspondent 12 minutes ago TORONTO (Reuters) - There is no vaccine against AIDS and none of the dozens of vaccines being tested is likely to completely protect people from the deadly virus, but the future looks bright for AIDS vaccine development, researchers said on Tuesday. Scientists will learn from the vaccines now being tested, and the developing world, hardest hit by HIV, is starting to produce its own vaccine effort, said Dr. Seth Berkley, head of the nonprofit International AIDS Vaccine Initiative. "An AIDS vaccine is the only tool that can end the pandemic," Berkley told a news conference to launch a biennial report on vaccines at the 16th International AIDS Conference in Toronto. "All evidence suggests that a vaccine is possible. There is progress being made. It's slow but it's steady," he added. "To me, we are about to enter a renaissance in AIDS vaccine research." Yet Berkley said only two AIDS vaccine candidates are in advanced human trials -- one made by Merck and Co. and another by Sanofi-Aventis SA. "The next major milestone for the field is likely to be the Merck result, which is a test for cellular immunity," Berkley said. Berkley and others do not expect the Merck vaccine will protect against disease in the way, for instance, a measles vaccine does. The AIDS virus infects more than 39 million people globally, more than 60 percent of them in sub-Saharan Africa. It kills more than 4 million people every year and has killed 25 million people since it was identified in the 1980s. It is difficult to vaccinate against because the virus infects the very immune system cells that are usually stimulated by a vaccine. "This is probably the toughest adversary that has ever been out there for vaccine development," Berkley said. Most vaccine stimulate antibodies, immune system proteins that mark enemy invaders for destruction. Vaccine researchers believe that a good AIDS vaccine will have to stimulate both antibodies and so-called cellular immunity, which is the job of T-cells, dendritic cells and other immune cells. Berkley hopes results of how well the Merck vaccine works will be available in 2008. If it reduces infection rates by even a little, scientists can study the volunteers and see just what successful aspects could be used as clues for further research. If it does not work at all, whole new approaches will have to be pursued. Even a partially effective vaccine could be useful, said Stephen Lewis, the United Nations delegate to Africa for AIDS. "I think it's fair to say ... even a modestly effective vaccine could cut the number of new infections by one-third over a decade, saving tens of millions of lives," Lewis told the news conference.news.yahoo.com/s/nm/20060816/ts_nm/ai...
B&M Gates place bets for HIV vaccines (4 Ratings) 2-Aug-06 04:46 pm And the winners are....www.dukemednews.org/filebank/2006/07/... Lots of genetic vaccines. No DNA vaccines? messages.finance.yahoo.com/Healthcare...
Zucht.... ik kan het niet laten, met excuses t.a.v. allen die zich hier aan storen: Zie posting, d.d. 28 juli:www.iex.nl/forum/topic.asp?forum=228&...
flosz schreef:
Zucht.... ik kan het niet laten, met excuses t.a.v. allen die zich hier aan storen:
Zie posting, d.d. 28 juli:
www.iex.nl/forum/topic.asp?forum=228&... Potjandorie, weer geen primeur!
Beste Flosz Misschien moet jij je mailadres wereldkundig maken en te beginnen hier op het forum. Mocht er een speurneus zijn, dan kan hij/zij eerst even jouw archief raadplegen ten einde zeker te weten of het hier om de laatste updates gaan of de postings(meestal door jouw) al gedaan zijn. (hele dikke lol) Erik
*DJ Vical Launches Phase I Trial Of HIV-Related Vaccine>VICL 08/22/2006 Dow Jones News Services (Copyright © 2006 Dow Jones & Company, Inc.) (MORE TO FOLLOW) Dow Jones Newswires 08-22-06 0730ET Copyright (c) 2006 Dow Jones & Company, Inc. *DJ Vical Launches Phase I Trial Of 'Prime Boost' Vaccine>VICL
Vical DNA Delivery Technology Enters Clinical Trial for Therapeutic HIV Vaccine SAN DIEGO, Aug. 22 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) announced today the initiation of a National Institutes of Health (NIH) sponsored Phase 1 clinical trial of a "prime-boost" vaccine approach designed to prevent or control disease in patients already infected with HIV. The trial involves priming an immune response with multiple doses of a plasmid DNA vaccine, based on Vical's proprietary DNA delivery technology, and boosting the response with a single dose of adenoviral vector vaccine given at a later date. The vaccine was developed by scientists at the Dale and Betty Bumpers Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, and was manufactured by Vical. The vaccine incorporates HIV genetic material from the three most globally important HIV subtypes, clades A, B and C, which are involved in about 85 percent of all HIV infections around the world. The same vaccine is currently being tested in a preventive setting through a multinational Phase 2 trial initiated in October 2005. Results from a Phase 1 trial in HIV-uninfected subjects showed that the prime-boost approach was well tolerated and effective in producing potent cellular and antibody immune responses, including specific responses against each of the HIV subtypes. The new Phase 1 trial is the first therapeutic application of a "prime/boost" vaccine against HIV in the VRC program. "Antiviral drugs have dramatically improved the outlook for HIV-infected individuals," said Vijay B. Samant, Vical's President and Chief Executive Officer, "but complicated treatment regimens, serious side effects and increasing drug resistance call for better long-term solutions. A post-infection vaccine that would allow the immune system to suppress viral loads could provide significant benefits both to prevent disease symptoms in the individual and potentially to reduce disease transmission between individuals. We are excited that our collaborators at the VRC have advanced into human testing with this novel vaccine application." The vaccine used in the Phase 1 trial incorporates parts of four HIV genes. Three of these vaccine components are modified versions of HIV genes called gag, pol and nef, synthetically made based on sequence from clade B, the subtype that predominates in Europe and North America. The fourth vaccine component is a modified version of the HIV gene named env. The env gene codes for a protein on the outer coat of the virus that allows it to recognize and attach to human cells. VRC scientists were the first to combine modified env from clades A and C, which are the most common in Africa and parts of Asia, with the modified env gene from clade B. The study is being conducted at the NIH Clinical Center. The trial is double-blinded and placebo-controlled, and will evaluate safety, tolerability and immune response. Subjects will continue highly active antiretroviral therapy (HAART) throughout the trial. Vical has produced multiple DNA vaccines for the VRC against infectious disease targets including Ebola, severe acute respiratory syndrome (SARS), and West Nile virus, all of which have advanced into Phase 1 clinical trials over the past three years. D.
DJ GenVec Says NIH Plans Human Trials Of HIV Treatment 08/22/2006 Dow Jones News Services (Copyright © 2006 Dow Jones & Company, Inc.) DOW JONES NEWSWIRES GenVec Inc. (GNVC) said Tuesday that the first human therapeutic clinical trial for a potential HIV vaccine involving the company's adenoviral-vector technology will be conducted by the National Institutes of Health's vaccine research center. The 15 HIV-positive patients will first be treated with a DNA "prime" vaccine, then will be given a second, "boost" vaccine, which was developed using GenVec's DNA carrier-based technology. Shares of GenVec, Gaithersburg, Md., were up 12% Tuesday, recently trading at $1.15, up 12 cents from Monday's close. -Carolyn Pritchard; 415-439-6400; AskNewswires@dowjones.com Dirk
The Aids vaccine field - Major players. PHARMACEuTICAL CoMPANIES GlaxoSmithKline GlaxoSmithKline (www.gsk.com) has focused its AIDS vaccine development efforts on recombinant protein vaccine candidates and has conducted trials of a gp120 plus NefTat fusion protein. In addition, GSK has an active program in the development of adjuvants for recombinant protein vaccines. GSK has recently diversified its portfolio to include nonhuman primate adenovirus and measles vectors as vaccine candidates. Merck The Merck (www.merck.com) AIDS vaccine research program is focusing on replication-defective recombinant adenovirus vectors. In collaboration with HVTN, its lead candidate has begun a collaborative Phase IIb study at both Merck and HVTN clinical trial sites in North and South America, the Caribbean, and Australia. Merck has also tested a series of DNA candidates in trials, evaluating copolymer and alum adjuvants aimed at enhancing the immunogenicity of DNA vaccines in humans. Finally, Merck has teamed with sanofi-aventis to evaluate a vaccination strategy of adenovirus vectors to prime and canarypox vectors to boost. sanofi–aventis Sanofi-aventis (http://en.sanofi-aventis.com) has focused its AIDS vaccine design efforts on optimizing candidate vaccines based on its proprietary position in recombinant viral vectors, specifically canarypox vectors, the most advanced of which are in Phase III clinical trials. BIoTECHNoLoGy CoMPANIES Wyeth (www.wyeth.com) has focused its AIDS vaccine research on DNA technology adjuvanted with IL-12, DNA followed by synthetic peptide boost, and vesicular stomatitis virus (VSV) as a live vaccine delivery vehicle. The VSV research program is in collaboration with Yale University. Wyeth has conducted clinical trials of DNA and peptide candidates. Advanced BioScience Laboratories (www. ablinc.com) is a biotechnology company that specializes in biomedical research with a focus on virology. ABL has entered into a multi year agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to perform preclinical development of promising HIV-1 vaccines and microbicides. AlphaVax (www.alphavax.com) is developing new vaccine technology with broad applications against infectious disease, cancer, and biodefense threats which have the potential to redefine vaccines and the role they play in medicine. AlphaVax uses a specialized viral vector system to make alphavirus replicon vaccines called alphavaccines, which have shown excellent protection in multiple models for infectious disease. Crucell (www.crucell.com) is a biotechnology company focused on research, development, production, and worldwide marketing of vaccines and antibodies that combat infectious diseases. The AdVac vectors, adenovirus serotypes 11 and 35, have shown promising results as vectors for AIDS vaccines in a series of studies by Crucell in collaboration with Harvard Medical School. Crucell has entered into an exclusive license agreement with IAVI to develop this technology and a cell line for the production of adenovector-based vaccines. GeoVax (www.geovax.com) is a biotechnology company developing vaccines for HIV-1 and other infectious agents. Successful Phase I clinical trials of a DNA vaccine have demonstrated the safety of this vaccine. Phase Ia/Ib trials to test various combinations of DNA and MVA AIDS vaccines in volunteers for safety and immonogenicity are planned for 2006. FIT Biotech (www.fitbiotech.com) is an innovative medical biotechnology company engaged in the development and commercialization of its proprietary Gene Transport Unit (GTU) technology and GTU product applications in DNA vaccination as well as in immuno-and gene therapies. FIT Biotech’s HIV DNA therapeutic vaccine candidate has advanced to a Phase II trial in collaboration with Chris Hani Baragwanath Hospital, Pediatric Research Centre, Soweto, South Africa. Maxygen (www.maxygen.com) is developing a preventive HIV vaccine. Its “MolecularBreeding” directed evolution platform generates novel HIV-1 antigens potentially capable of inducing broad antibody responses to multiple strains of the HIV-1 virus. An SBIR award funds investigations into the effect on immunogenicity of secondary modifications to a specific HIV-1 envelope protein. A grant from the Department of Defense funds work to develop a high-throughput HIV vaccine screening platform. Mymetics (www.mymetics.com) is developing vaccines and therapies to combat AIDS. Its lead vaccine candidate combines the company’s HIV-1 gp41derived peptide antigen grafted onto virosomes. Previous research has demonstrated that virosome-based vaccine technology is able to elicit protective antibodies in various anatomical compartments, which may prevent HIV translocation across mucosal tissues. Targeted Genetics (www.targetedgenetics.com) is a biotechnology company focused on the development of innovative targeted molecular therapies. Targeted Genetics, in collaboration with IAVI, Columbus Children’s Research Institute, and Children’s Hospital of Philedelphia, is pursuing development of an AIDS vaccine, tgAAC09, a recombinant vaccine candidate that delivers select genes from HIV packaged within the capsid of an adeno-associated virus (AAV). Therion Biologics (www.therionbio.com) is engaged in the development of therapeutic vaccines for cancer and preventive vaccines for AIDS. Therion is developing a preventive AIDS vaccine based on the MVA pox virus vector for IAVI. Vical (www.vical.com) researches and develops bio- pharmaceutical products based on DNA delivery technol- ogies. In 2003, Vical entered into a subcontract agree- ment to manufacture bulk DNA vaccines for the VRC. Virax (www.virax.com.au) is an early-stage-devel- opment biopharmaceutical company focusing on the development of immunotherapeutics for the treatment of autoimmune disorders, HIV/AIDS, cancers, and infectious diseases. Virax’s preventive HIV program is focused on a recombinant fowl pox virus designed to co-express genes for immunogenic but highly conserved parts of the HIV-1 virus in conjunction with a human cytokine (interferon gamma). www.iex.nl/forum/topic.asp?forum=228&...
*DJ Interim Data From Targeted Genetics' Phase I HIV/AIDS Vaccine Trial To Be Presented At Leading European AIDS Vaccine Meeting; Vaccine Candidate Well Tolerated; Modest Immune Response Observed In A Subset Of Patients>TGEN 08/30/2006 Dow Jones News Services (Copyright © 2006 Dow Jones & Company, Inc.) Dirk
DJ Vical Says Study Shows Broad T-Cell Immunity Against HIV Generated In Prime-Boost Vaccine Phase 1 Trial>VICL 08/31/2006 Dow Jones News Services Dirk
( BW)(MD-GENVEC)(GNVC) Data from Multiple Phase I Trials Incorporating GenVec Technology Presented at International AIDS Conference; Safety and Immunogenicity Data Presented by NIH VRC and HVTN Business Editors/Health/Medical Writers BIOWIRE2K GAITHERSBURG, Md.--(BUSINESS WIRE)--Aug. 31, 2006--GenVec, Inc. (NASDAQ: GNVC) announced today that results from multiple Phase 1 clinical trials were presented at the AIDS Vaccine 2006 Conference in Amsterdam this week. The HIV vaccine incorporating GenVec's adenovector-based technology was well tolerated, and results were consistent with previously reported data: induction of potent immune responses when the vaccine was used alone or in combination with a DNA primer vaccine. The results support the rationale for advanced clinical testing. In a study of the HIV vaccine incorporating GenVec's adenovector-based technology given to 40 volunteers as a single dose of either 1e10 Particle Units (PU) or 1e11 PU, both doses showed stimulation of T-cells against the multiple antigens contained in this vaccine. The study was presented by Dr. Larry Peiperl of University of California School of Medicine San Francisco, and the study was conducted by the HIV Vaccine Trials Network (HVTN). In a second study presented by Dr. Richard Koup of the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, cellular immune responses were analyzed in 14 volunteers given a DNA prime followed by a boost with the HIV vaccine incorporating GenVec's adenovector technology. Dr. Koup reported that these data indicate that the combination of priming and boosting produces more polyfunctional T-cells than either modality alone. "Polyfunctional T-cells are a hallmark of existing vaccines such as the effective smallpox vaccine and are also believed to be important for an effective HIV vaccine. A similar breadth of polyfunctional T-cells occurs in patients who have HIV but do not progress rapidly to AIDS," commented Dr. Rick King, GenVec's Senior VP of Research. In addition to the clinical presentations described above, there were presentations given by Drs. Gary Nabel and John Mascola of the VRC highlighting several next generation HIV vaccine approaches using GenVec adenovector technology. GenVec, Inc. is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Additional information on GenVec and its portfolio of product candidates is available atwww.genvec.com and in the company's various filings with the Securities and Exchange Commission. Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future programs and studies, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; the timing and content of future U.S. Food and Drug Administration regulatory actions with respect to GenVec, its product candidates, or collaborators, risks relating to the commercialization, if any, of GenVec's proposed product candidates (such as marketing, regulatory, patent, product liability, supply, competition and other risks); dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available atwww.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements. CONTACT: GenVec, Inc. Investor Relations: Tricia J. Richardson, 240-632-5511 trichardson@genvec.com
*DJ Data From Multiple Phase I Trials Incorporating GenVec Technology Presented At Intl AIDS Conference; Safety And Immunogenicity Data Presented By NIH VRC And HVTN>GNVC 08/31/2006 Dow Jones News Serviceswww.genvec.com/download/press/FinalOu... Dirk
DJ Vical Says "Prime-Boost" Vaccine Effective In HIV Study DOW JONES NEWSWIRES Vical Inc. (VICL) said a "prime-boost" vaccine regimen tested in 40 HIV-uninfected subjects was safe, well-tolerated and "highly effective" in inducing T-cell immune responses during a Phase I trial. The San Diego-based pharmaceutical company said the trial involved priming an immune response with three doses of a plasmid DNA vaccine, which was based on Vical's proprietary DNA-delivery technology, and boosting the response with a single dose of adenoviral-vector vaccine given at a later date. Vical said the prime-boost vaccine regimen was effective in generating multiple types of HIV-specific T-cell immune responses. -Adam Kuczynski; 201-938-5400; AskNewswires@dowjones.com (END) Dow Jones Newswires 08-31-06 0751ET
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
910,59
+0,71%
EUR/USD
1,0771
0,00%
FTSE 100
8.433,76
+0,63%
Germany40^
18.773,50
+0,47%
Gold spot
2.360,72
0,00%
NY-Nasdaq Composite
16.340,87
-0,03%
Stijgers
Dalers